What CAMMED THERAPEUTICS LTD. does

CamMed Therapeutics Ltd. is a UK-based, privately held RNA biotechnology company founded in late 2023 by Dr. Ahmet C. Berkyurek and Dr. Andreas W. Claas, headquartered at the Stevenage Bioscience Catalyst in Hertfordshire. The company develops a single integrated product platform called RNARISE™, a proprietary non-viral self-amplifying RNA technology positioned as a fourth-generation mRNA approach. RNARISE is built around a novel RNA-dependent RNA polymerase (replicase) identified through an AI-assisted screening pipeline that evaluated over 2,200 candidates; the construct is designed to self-amplify inside target cells, enabling therapeutically meaningful protein expression at smaller doses while bypassing double-stranded RNA intermediates that drive innate immune activation and toxicity in conventional mRNA therapeutics.

The company's stated scientific focus is on rare diseases with high unmet need, with Sanfilippo Syndrome (MPS III) identified as a primary indication, alongside broader applications across vaccines, therapeutics, and gene therapies. CamMed holds a registered UK trademark for RNARISE™ (UKIPO UK00004362536) and has a patent application pending with UKIPO covering the platform technology. The company is operating pre-revenue with a small team — a Co-founder & CEO, Co-founder & CTO, CSO, Senior Scientist, and an ESRC Fellow Intern, with two scientific hires added after the pre-seed round.

CamMed operates a B2B enterprise licensing and partnership model, targeting pharmaceutical and biotech companies seeking next-generation RNA platform technology, with pricing conducted on a quote-based, non-publicly-disclosed basis and revenue expected to flow through licensing royalties and co-development partnerships. The company closed a pre-seed funding round in February 2026 with Zinc VC, SFC Capital, and KQ Labs at the Francis Crick Institute, and has publicly positioned itself through a royal visit from HRH The Duchess of Edinburgh in May 2026, Business Weekly and Cambridge Independent Business Awards shortlistings in 2025, and KQ Labs Accelerator selection.

Name

CAMMED THERAPEUTICS LTD.

Legal name

CamMed Therapeutics Ltd.

Website

https://cammed.co.uk

Company type

Private

Founded year

2023

Operating status

Operating

Short description

CamMed Therapeutics Ltd. is a UK pre-revenue biotech developing RNARISE™, an AI-assisted non-viral self-amplifying RNA platform targeting rare diseases such as Sanfilippo Syndrome, with a B2B licensing model serving pharmaceutical and biotech partners.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Self-amplifying RNA therapeutics
• Biotech platform licensing
• Rare disease therapies
• AI-driven RNA design
• Non-viral RNA delivery

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Platform Licensing: Pre-revenue biotech seeking to monetize through licensing agreements with pharmaceutical and biotech companies for platform technology and therapeutic pipeline development.
2. Therapeutic Development Partnerships: Future revenue through co-development partnerships and licensing deals for specific disease applications including rare diseases like Sanfilippo Syndrome.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CamMed Therapeutics develops and licenses the RNARISE™ platform, a proprietary AI-enabled non-viral self-amplifying RNA technology designed to address key limitations of existing mRNA therapeutics, including toxicity, poor tissue targeting, and manufacturing complexity. The platform is offered to pharmaceutical and biotech partners for vaccines, therapeutics, and gene therapies, with the company's own pipeline initially targeting rare diseases such as Sanfilippo Syndrome.

Product overview

CamMed Therapeutics Ltd. offers a single unified product platform called RNARISE™, an AI-powered proprietary non-viral self-amplifying RNA technology designed to create safer, faster, more effective, and more accessible RNA vaccines and therapeutics. The platform enables self-amplification inside target cells using a novel RNA-dependent RNA polymerase, bypassing the double-stranded RNA intermediates that drive innate immune activation and toxicity in existing approaches. The company focuses on rare diseases, with Sanfilippo Syndrome identified as one of their first target indications.

Differentiator

Problem solved

Functional benefit

Brands

• RNARISE™: Proprietary non-viral self-amplifying RNA platform - a fourth-generation mRNA technology addressing key limitations of existing RNA therapeutic approaches, including toxicity, poor tissue targeting, and manufacturing complexity.

Products and services

• RNARISE™ Platform

Quantifiable outcome

• Smaller initial dose required to achieve therapeutically meaningful protein expression compared to conventional mRNA

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

One partnership is on record.

• Stevenage Bioscience CatalystcoreStrategic or Co-development PartnerHost organisation providing laboratory facilities and ecosystem for CamMed's R&D operations. Located at Gunnels Wood Road, Stevenage, offering access to life sciences cluster infrastructure and resources.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ziphius Vaccines: European (Belgian) biotech developing self-amplifying RNA-based vaccines and therapeutics. Closely comparable to CamMed as a regional, early-stage saRNA platform company pursuing pharma licensing.
• Ethris: Germany-based biotech developing RNA-based therapeutics with proprietary stabilization and delivery technology. Comparable to CamMed in being a European, platform-stage RNA therapeutics company targeting respiratory and rare diseases.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company developing self-amplifying RNA therapeutics and vaccines, including a partnered COVID/flu program with CSL/Seqirus. Most direct competitor to CamMed in the saRNA therapeutics space.
• Replicate Bioscience: Clinical-stage biotech developing self-replicating RNA therapeutics and vaccines across oncology and infectious disease. Directly comparable to CamMed's saRNA platform and licensing-focused business model.
• Strand Therapeutics: Developer of self-amplifying RNA therapeutics designed to deliver genetic medicines with programmable, long-lasting effects. Competes in the same saRNA modality and indication overlap (oncology, rare disease).

Emerging players

• Stoke Therapeutics: Clinical-stage biotech developing antisense oligonucleotide (ASO)-mediated therapies for rare genetic diseases, including Sanfilippo Syndrome. Directly comparable to CamMed's lead indication target and RNA-based therapeutic approach.
• Verve Therapeutics: Clinical-stage genetic medicines company developing in vivo gene-editing therapies for cardiovascular disease. Comparable as an AI- and platform-driven genetic medicine developer that licenses/partner-validates its technology with major pharma.

Broad incumbents

• CureVac: Clinical-stage biopharmaceutical company developing mRNA-based vaccines and therapeutics, including proprietary optimized mRNA and saRNA approaches. Comparable as an established RNA platform player with potential licensing overlap.
• BioNTech: Major mRNA therapeutics company with deep pipeline across cancer, infectious disease, and rare diseases. A potential strategic acquirer or licensing partner for CamMed's differentiated saRNA platform.
• Moderna: Established leader in mRNA vaccines and therapeutics with broad pipeline and manufacturing scale. Represents both the dominant incumbent CamMed must compete against and a potential licensing partner for next-generation saRNA technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cambridge-medixine-ltd/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CAMMED THERAPEUTICS LTD.